Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Net Cash Flow (2016 - 2026)

Relmada Therapeutics has reported Net Cash Flow over the past 3 years, most recently at -$3540.0 for Q1 2014.

  • Quarterly Net Cash Flow fell 20.33% to -$3540.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was -$17704.0 through Feb 2014, down 749.69% year-over-year, with the annual reading at -$360486.0 for FY2025, 53.7% down from the prior year.
  • Net Cash Flow was -$3540.0 for Q1 2014 at Relmada Therapeutics, up from -$9124.0 in the prior quarter.
  • Over five years, Net Cash Flow peaked at $7514.0 in Q2 2012 and troughed at -$9124.0 in Q4 2013.
  • The 3-year median for Net Cash Flow is -$3344.0 (2012), against an average of -$2139.9.
  • Year-over-year, Net Cash Flow plummeted 709.49% in 2013 and then dropped 20.33% in 2014.
  • A 3-year view of Net Cash Flow shows it stood at $1497.0 in 2012, then crashed by 709.49% to -$9124.0 in 2013, then skyrocketed by 61.2% to -$3540.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Net Cash Flow are -$3540.0 (Q1 2014), -$9124.0 (Q4 2013), and -$5040.0 (Q2 2013).